Genetic Variation in TRAF3IP2 (rs13190932)

Sponsor
South Valley University
Study ID
NCT07086924
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • Methotrexate — DRUG
    Assessing the response of psoriasis and psoriatic arthritis to Methotrexate. and also Assessing the pharmacogenetic association between TRAF3IP2 ( rs13190932 ) gene Polymorphism in psoriatic and psoriatic arthritis patients taking Methotrexate.

Study Details

Psoriasis is an immune-mediated inflammatory disease that is highly prevalent worldwide, affecting approximately 2-3% of the world population. It is characterized by red, scaly plaques that can appear on various parts of the body, causing significant physical and psychological burden to affected individuals. The Pathogenesis of PsA involves a complex interplay of genetic, immunological, and environmental factors.Genetic studies have identified several susceptibility loci, including HLA-Cw6 and IL23R, which are shared with psoriasis. Additionally, the presence of certain alleles, such as HLA-B27, is associated with a more severe disease course and a higher likelihood of axial involvement.

Key Dates

First listed
Jul 25, 2025
Start date
Jun 1, 2025
Status verified
Jun 2025
Primary completion
Jun 1, 2026
Completion
Jun 10, 2026

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Group A
    About 30 patients suffering from psoriasis
  • Active Comparator: Group B
    About 10 patients suffering from psoriatic arthritis
  • Experimental: Group C
    About 10 healthy control group

Primary Outcome Measure

Treatment of Psoriasis and Psoriatic arthritis [ Time Frame: 3 months ]

Central Contacts

Find similar trials

Nationwide
Psoriasis trialsPsoriatic arthritis trialsDermatology trialsRheumatology trialsAutoimmune disease trialsMusculoskeletal disorders trials

Related Studies